`Patent Owner Mandatory Notices
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`AGILA SPECIALTIES INC. and MYLAN LABORATORIES LIMITED,
`
`Petitioners
`
`v.
`
`CEPHALON, INC.,
`
`Patent Owner
`
`Case: IPR2016-00026
`Patent No. 8,791,270
`
`PATENT OWNER’S MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8(a)(2)
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`United States Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00026
`Patent Owner Mandatory Notices
`
`
`Pursuant to 37 C.F.R. § 41.8(a)(2), Patent Owner Cephalon, Inc. hereby
`
`submits the following mandatory notices. This paper is timely filed within 21
`
`days of service of the petition.
`
`I.
`
`REAL PARTY IN INTEREST (37 C.F.R. § 41.8(b)(1))
`
`Cephalon, Inc. is the patent owner and real party-in-interest. Cephalon is
`
`an indirect wholly owned subsidiary of Teva Pharmaceuticals Industries Ltd.
`
`II. RELATED MATTERS (37 C.F.R. § 41.8(b)(2))
`
`a. Judicial Matters
`
`The following proceedings may affect or be affected by a decision in
`
`this proceeding:
`
`Case
`
`Number
`
`Court
`
`Cephalon, Inc. v. Panacea Biotech, Ltd.
`
`1-15-cv-00735 DED
`
`Cephalon, Inc. v. Apotex, Inc.
`
`Cephalon, Inc. v. Sun Pharma Global FZE, et al
`
`Cephalon Inc. v. Hospira Inc.
`
`1-15-cv-00404 DED
`
`1-14-cv-01243 DED
`
`1-14cv-01242 DED
`
`Cephalon, Inc. v. Dr. Reddy's Laboratories, Ltd., et al
`
`1-14-cv-01241 DED
`
`(dismissed)
`Cephalon Inc. v. Sandoz Inc.
`
`(dismissed)
`
`1-14-cv-01239 DED
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00026
`Patent Owner Mandatory Notices
`
`
`Cephalon, Inc. v. InnoPharma Inc.,
`
`1-14-cv-01238 DED
`
`Cephalon, Inc. v. Agila Specialties Inc., f/b/a/ Strides,
`
`1-14-cv-01237 DED
`
`1-14-cv-01332 DED
`
`1-14-cv-05180 NYED
`
`1-14-cv-01116 DED
`
`
`
`DED
`
`
`
`1-14-cv-01117
`
`1-14-cv-01045 DED
`
`1-14-cv-00671
`
`
`
`DED
`
`1-14-cv-00568 DED
`
`1-14-cv-00122 DED
`
`1-13-cv-02095 DED
`
`1-13-cv-02080 DED
`1-13-cv-02046 DED
`
`Cephalon, Inc. v. Wockhardt Bio Ltd., et al
`
`(dismissed)
`Cephalon, Inc. v. Nang Kuang Pharmaceutical Co., Ltd.,
`
`et al
`Cephalon, Inc. v. Sagent Pharmaceuticals, Inc., et al
`
`Cephalon, Inc. v. Nang Kuang Pharmaceutical Co., Ltd.
`
`et al (dismissed)
`
`Cephalon, Inc. v. Eurohealth International Sarl, et al
`
`Cephalon, Inc. v. Breckenridge Pharmaceutical, Inc., et
`
`
`
`al (dismissed)
`Cephalon, Inc. v. Uman Pharma Inc.
`
`(dismissed)
`Cephalon, Inc. v. Actavis LLC f/k/a Actavis Inc., et al
`
`(dismissed)
`Cephalon, Inc. v. Accord Healthcare, Inc., et al
`
`Cephalon Inc. v. Agila Specialties Inc., et al
`Cephalon Inc. v. Hetero Labs Ltd., et al
`
`
`
`
`
`
`
`
`
`IPR2016-00026
`Patent Owner Mandatory Notices
`
`
`On November 24, 2014 and April 5, 2015, the District of Delaware matters
`
`identified in the table above (excluding 15-cv-00404 and 15-cv-00735), and
`
`including Cephalon Inc. v. Eagle Pharmaceuticals Inc., Civil Action No. 13-cv-
`
`1738; Cephalon Inc. v. InnoPharma Inc., Civil Action No. 13-cv-2081;
`
`Cephalon, Inc. v. Dr. Reddy's Laboratories, Ltd., et al, Civil Action No. 13-cv-
`
`2082; Cephalon, Inc. v. Glenmark Pharmaceuticals Ltd. et al, Civil Action No.
`
`13-cv-2093; Cephalon Inc. v. Hospira Inc., Civil Action No. 13-cv-2094;
`
`Cephalon, Inc. v. Sun Pharma Global FZE et al, Civil Action No. 13-cv-2096;
`
`Cephalon Inc. v. Sandoz Inc.,Civil Action No. 13-cv-2103 (dismissed); Cephalon,
`
`Inc. v. Sun Pharma Global FZE et al, Civil Action No. 14-cv-0333; Cephalon,
`
`Inc. v. Dr. Reddy's Laboratories, Ltd. et al, Civil Action No. 14- cv-0334;
`
`Cephalon, Inc. v. Emcure Pharmaceuticals, Ltd. et al, Civil Action No. 14-cv-
`
`0335; Cephalon Inc. v. InnoPharma Inc., Civil Action No. 14-cv-0590; Cephalon
`
`Inc. v. Eagle Pharmaceuticals Inc., Civil Action No. 14-cv-1042; Cephalon, Inc.
`
`v. Agila Specialties, Inc. et al., Civil Action No. 14-cv-1237; Cephalon Inc. v.
`
`InnoPharma Inc., Civil Action No. 14-cv-1238; Cephalon, Inc. v. Sandoz, Inc.,
`
`Civil Action No. 14-cv-1239; Cephalon, Inc. v. Dr. Reddy's Laboratories, Ltd. et
`
`al, Civil Action No. 14-cv-1241; Cephalon Inc. v. Hospira Inc., Civil Action No.
`
`14-cv-1242; Cephalon, Inc. v. Sun Pharma Global FZE et al, Civil Action No.
`
`14-cv-1243; Cephalon Inc. v. Sandoz Inc. et al, Civil Action No. 15-cv-00178;
`
`
`
`
`
`
`
`
`IPR2016-00026
`Patent Owner Mandatory Notices
`
`
`and Cephalon, Inc. v. Dr. Reddy's Laboratories, Ltd. et al, Civil Action No. 15-
`
`cv-00179) were consolidated into a single case styled In Re Bendamustine Cases,
`
`Civil Action No. 13-cv-2046 (GMS).
`
`b. Administrative Matters
`
`U.S. Patent No. 8,791,270 claims priority to U.S. Patent No. 8,436,190, which
`
`
`
`
`
`is currently under review in Case No. IPR2015-00503. The ’270 Patent also claims
`
`priority to U.S. Patent No. 8,461,350 and U.S. Provisional Patent Application No.
`
`60/644,354. U.S. Patent No. 8,895,756 and U.S. Patent No. 8,609,863 also claim
`
`priority to U.S. Provisional Patent Application No. 60/644,354.
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00026
`Patent Owner Mandatory Notices
`
`
`III. LEAD AND BACKUP COUNSEL (37 C.F.R. § 41.8(b)(3))
`
`Lead Counsel
`
`Back-up Counsel
`
`Ira J. Levy
`
`
`
`(Reg. No. 35,587)
`
`Eleanor M. Yost
`
`
`
`(Reg. No. 58,013)
`
`GOODWIN PROCTER LLP
`
`GOODWIN PROCTER LLP
`
`901 New York Avenue NW
`
`The New York Times Building
`
`Washington, DC 20001
`
`620 Eighth Avenue
`
`
`
`New York, New York 10018-1405
`
`eyost@goodwinprocter.com
`
`Fax: 212-355-3333
`
`ilevy@goodwinprocter.com
`
`IV. SERVICE INFORMATION (37 C.F.R. § 41.8(b)(4))
`
`Please direct all correspondence to counsel at the contact information above.
`
`Petitioner consents to service by electronic mail at eyost@goodwinprocter.com
`
`and ilevy@goodwinprocter.com.
`
`
`
`
`
`Tel: 212-813-8800
`
`
`
`Tel: 202-346-4000
`
`
`
`Fax: 2022-346-4444
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: October 30, 2015
`
`IPR2016-00026
`Patent Owner Mandatory Notices
`
`
`Respectfully Submitted,
`GOODWIN PROCTER LLP
`
`/Eleanor M. Yost/
`(Reg. No. 58,013)
`901 New York Avenue NW
`Washington, D.C. 20001
`Tel: 202-346-4000
`Fax: 202-346-4444
`
`Attorneys for Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00026
`Patent Owner Mandatory Notices
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing document captioned
`
`“PATENT OWNER’S MANDATORY NOTICES” was served electronically via
`
`e-mail on this 30th day of October, 2015, as follows:
`
`Steven W. Parmelee
`sparmelee@wsgr.com
`WILSON SONSINI GOODRICH & ROSATI
`
`Michael T. Rosato
`mrosato@wsgr.com
`WILSON SONSINI GOODRICH & ROSATI
`
`Nicole Stafford
`nstafford@wsgr.com
`WILSON SONSINI GOODRICH & ROSATI
`
`Dated: October 30, 2015
`
`/Eleanor M. Yost/
`Eleanor M. Yost (Reg. No. 58,013)
`GOODWIN PROCTER LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`